on Friday issued a clarification through an exchange filing in response to media reports suggesting that the company was considering a merger of its unlisted subsidiary Biocon Biologics Ltd (BBL) with the parent entity, along with potential IPO and share-swap options.

The company stated that the reports referred to its earlier communication from May this year, reiterating that a formal process is still underway. "This is with reference to the news published / appearing in the mainstream media w.r.t. Biocon Limited (BL) considering merging Biocon Biologics Ltd (BBL), an unlisted subsidiary of the Company, IPO and share swap options," Biocon said. Advertisement

Highlighting its May 8, 2025, release, the company noted that its Board had set up a committee to explore restructuring possibili

See Full Page